Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger

Cancer Research

Volumn 58, Issue 1, 1998, Pages 159-165

  Wu, Jun ^a   Akaike, Takaaki ^a   Maeda, Hiroshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ARGININE; BRADYKININ; BRADYKININ ANTAGONIST; CYCLOOXYGENASE 2; DRUG VEHICLE; EVANS BLUE; ICATIBANT; IMIDAZOLINE DERIVATIVE; INDOMETACIN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SCAVENGER; SODIUM CHLORIDE; TEMOCAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES TUMOR; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CONTRAST MEDIUM EXTRAVASATION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SARCOMA; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VASCULARIZATION;

ANIMALS; ARGININE; ASCITES; BRADYKININ; CAPILLARY PERMEABILITY; CYCLIC N-OXIDES; CYCLOOXYGENASE INHIBITORS; FREE RADICAL SCAVENGERS; IMIDAZOLES; INDOMETHACIN; MALE; MICE; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE; RECEPTORS, BRADYKININ; SARCOMA 180;

EID: 0031964923     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Matsumura, Y., and Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res., 46: 6387-6392, 1986.
2. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Delivery Rev., 6: 181-202, 1991.
3. Maeda, H. Polymer conjugated macromolecular drugs for tumor-specific targeting. In: A. J. Domb (ed.), Polymeric Site-specific Pharmacotherapy, pp. 96-116. New York: John Wiley & Sons, Inc., 1994.
4. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 255: 1182-1186, 1971.
5. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
6. Ohtani, H., and Sasano, N. Microvascular changes in the stroma of human colorectal carcinomas: ultrastructural histochemical study. Jpn. J. Cancer Res., 80: 360-365, 1989.
7. Suzuki, M., Takahashi, T., and Sato, T. Medial regression and its functional significance in tumor-supplying host arteries: a morphometric study of hepatic arteries in human livers with hepatocellular carcinoma. Cancer (Phila.), 56: 444-450, 1987.
8. Iwai, K., Maeda, H., and Konno, T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res., 44: 2115-2121, 1984.
9. Seymour, L. W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst., 9: 135-187, 1992.
10. Seymour, L. W., Flanagan, P. A., al-Shamkhani, A., Subr, V., Ulbrich, K., Cassidy, J., and Duncan, R. Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery. Sel. Cancer Ther., 7: 59-73, 1991.
11. Tabata, Y., Uno, K., Ikada, Y., and Muramatsu, S. Suppressive effect of recombinant TNF-gelatin conjugate on murine tumour growth in vivo. J. Pharm. Pharmacol., 45: 303-308, 1993.
12. Tabata, Y., Uno, K., Ikada, Y., Kishida, T., and Muramatsu, S. Potentiation of in vivo antitumor effects of recombinant interleukin-1 α by gelatin conjugation. Jpn. J. Cancer Res., 84: 681-688, 1993.
13. Shih, Y., Konrad, M. W., Warren, M. K., Childs, A., Paradise, C., Meyers, F. J., and Groves, E. S. Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2. Eur. J. Immunol., 22: 727-733, 1992.
14. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington DC), 219: 983-985, 1983.
15. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington DC), 246: 1306-1309, 1989.
16. Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., and Connolly, D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (Washington DC), 246: 1309-1312, 1989.
17. Nagy, J. A., Masse, E. M., Herzberg, K. T., Meyers, M. S., Yeo, K. T., Yeo, T. K., Sioussat, T. M., and Dvorak, H. F. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res., 55: 360-368, 1995.
18. 3]bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem., 263: 16051-16054, 1988.
19. Matsumura, Y., Kimura, M., Yamamoto, T., and Maeda, H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res., 79: 1327-1334, 1988.
20. Matsumura, Y., Maruo, K., Kimura, M., Yamamoto, T., Konno, T., and Maeda, H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res., 82: 732-741, 1991.
21. Moncada, S., Palmer, R. M. J., and Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 43: 109-137, 1991.
22. Brigham, K. L. Mediators of the inflammatory process: prostanoids. In: P. M. Henson and A. C. Murphy (eds.), Handbook of Inflammation, Vol. 6: Mediators of the Inflammatory Process, pp. 1-14. Amsterdam: Elsevier Science Publishers, B. V., 1989.
23. Hock, F. J., Wirth, K., Albus, U., Linz, W., Gerhards, H. J., Wiemer, G., Henke, S., Breipohl, G., Konig, W., Knolle, J., and Scholkens, B. A. Hoe 140, a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol., 102: 769-773, 1991.
24. Wirth, K., Hock, F. J., Albus, U., Linz, W., Alpermann, H. G., Anagnostopoulos, H., Henk, S., Breipohl, G., Konig, W., Knolle, J., and Scholkens, B. A. Hoe 140, a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol., 102: 714-717, 1991.
25. Akaike, T., Yoshida, M., Miyamoto, Y., Sato, K., Kohno, M., Sasamoto, K., Miyazaki, K., Ueda, S., and Maeda, H. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/NO through a radical reaction. Biochemistry, 32: 827-832, 1993.
26. Maeda, H., Noguchi, Y., Sato, K., and Akaike, T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res., 85: 331-334, 1994.
27. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
28. Akaike, T., Noguchi, Y., Ijiri, S., Setoguchi, K., Suga, M., Zheng, Y. M., Dietzschold, B., and Maeda, H. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. USA, 96: 2448-2453, 1996.
29. Takahashi, Y., Taketani, Y., Endo, T., Yamamoto, S., and Kumegawa, M. Studies on the induction of cyclooxygenase isozymes by various prostaglandins in mouse osteoblastic cell line with reference to signal transduction pathways. Biochim. Biophys. Acta, 1212: 217-224, 1994.
30. Maeda, H., and Yamamoto, T. Pathogenic mechanisms induced by microbial proteases in microbial infections. Biol. Chem. Hoppe-Seyler, 377: 217-226, 1996.
31. Nakano, S., Matsukado, K., and Black, K. L. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res., 56: 4027-4031, 1996.
32. 9-bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats. Br. J. Pharmacol., 109: 14-17, 1993.
33. Strausser, H. R., and Humes, J. L. Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumor induction in BALB/c mice. Int. J. Cancer, 15: 724-730, 1975.
34. Trevisani, A., Ferretti, E., Capuzzo, A., and Tomasi, V. Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumour growth by non-steroidal anti-inflammatory drugs. Br. J. Cancer, 41: 341-347, 1980.
35. Greenberg, E. R., Baron, J. A., Freeman, D. H., Jr, Mandel, J. S., and Haile, R. Reduced risk of large-bowel adenomas among aspirin users. J. Natl. Cancer Inst., 85: 912-916, 1993.
36. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52: 5575-5589, 1992.
37. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., and Hla, T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55: 3785-3789, 1995.
38. Meyer, R. E., Shan, S., DeAngelo, J., Dodge, R. K., Bonaventura, J., Ong, E. T., and Dewhirst, M. W. Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br. J. Cancer, 71: 1169-1174, 1995.
39. Tozer, G. M., Prise, V. E., and Chaplin, D. J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res., 57: 948-955, 1997.
40. Doi, K., Akaike, T., Horie, H., Noguchi, Y., Fujii, S., Beppu, T., Ogawa, M., and Maeda, H. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer (Phila.), 77: 1598-1604, 1996.
41. Burch, R. M., and Kyle, D. J. Recent developments in the understanding of bradykinin receptors. Life Sci., 50: 829-838, 1992.
42. Schlemper, V., and Calixto, J. B. Nitric oxide pathway-mediated relaxant effect of bradykinin in the guinea-pig isolated trachea. Br. J. Pharmacol., 111: 83-88, 1994.
43. Salvemini, D., Misko, T. P., Masferrer, J. L., Seibert, K., Currie, M. G., and Needleman, P. Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. USA, 90: 7240-7244, 1993.
44. 2 negatively modulates induction of nitric oxide synthase by interleukin 1. Proc. Natl. Acad. Sci. USA, 91: 12168-12172, 1994.
45. 2 and angiogenesis. Proc. Soc. Exp. Biol. Med., 161: 174-177, 1983.
46. Ziehe, M., Morbidelli, L., Masini, E., Amerini, S., Granger, H. J., Maggi, C. A., Geppetti, P., and Ledda, F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J. Clin. Invest., 94: 2036-2044, 1994.
47. Duncan, R., Connors, T. A., and Meada, H. Drug targeting in cancer therapy: the magic bullet, what next? J. Drug Targeting, 3: 317-319, 1996.